Double-Blind Comparison of Ketanserin with Placebo in Patients with Essential Hypertension

Wellens, D.; Peeters, G.; Baeten, B.; Sieben, G.; Symoens, J.
November 1986
Angiology;Nov1986, Vol. 37 Issue 11, p810
Academic Journal
Two double-blind multicenter trials were performed to compare the antihypertensive action of ketanserin, at an oral dosage of 20 mg three times daily, with that of placebo over a period of four to six weeks. A subset of patients was treated in a crossover fashion for either four weeks (36 patients) or six weeks (24 patients). The patients had essential hypertension, with a diastolic blood pressure ≫ 95 mmHg measured in sitting position at the end of a placebo run-in period of at least one week. In a first trial, 78 of 82 patients completed the four-week study period, where the mean drop of the systolic/diastolic blood pressure was -14/-12 mmHg in the ketanserin group (n=32) versus - 8 / - 5 mmHg in the placebo group (n = 46). This difference is statistically significant (p = 0.05/p < 0.01). In 13 patients who after the initial ketanserin treatment were further treated with placebo in crossover for four weeks, the blood pressure rose slightly (+1/+3 mmHg). In the alternative group (n=23), the blood pressure fell by -10/-7 mmHg after placebo and decreased further by -10/ - 8 mmHg after ketanserin. In a second trial, 24 patients completed a two by six week crossover treatment. In 12 patients assigned to the sequence placebo-ketanserin, there was a drop of the systolic/diastolic blood pressure by - 7 / - 4 mmHg after placebo and an additional drop by -26/-10 mmHg after ketanserin. In the other 12 patients, who received the sequence ketanserin-placebo, the blood pressure decreased by -21/-15 mmHg during ketanserin and rose again by +11/+8 mmHg during placebo. In both treatment groups, the antihypertensive action of ketanserin was significantly superior to that of placebo. The heart rate was not significantly influenced by ketanserin in any of these groups. Orthostatic hypotension was not observed in any of these patients. It is concluded that ketanserin is a well-tolerated antihypertensive agent, whose blood pressure-lowering effect is significantly superior to that of placebo.


Related Articles

  • Blood pressure management. Fallon, Noeleen // World of Irish Nursing & Midwifery;Apr2006, Vol. 14 Issue 4, p35 

    The article focuses on blood pressure management. It defines blood pressure as the pressure exerted within the blood vessel walls as the heart pumps and circulates the blood around the body. It defines hypertension as the level of blood pressure above which intervention has been shown to reduce...

  • Sitaxentan in Pulmonary Arterial Hypertension: A Viewpoint by Steven Kawut.  // Drugs;2007, Vol. 67 Issue 5, p771 

    The article discusses the author's viewpoint concerning the sitaxentan in pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) causes significant functional limitations and an increased risk of health. Endothelin (ET)-1 is increased both locally and systematically in patient...

  • Complications of hypertensive emergencies are usually reversible with prompt diagnosis and treatment.  // Drugs & Therapy Perspectives;Apr2004, Vol. 20 Issue 4, p10 

    Although systemic hypertension is a common clinical disorder, hypertensive emergencies occur relatively infrequently in clinical practice. However, when they do occur, it is vital that they are diagnosed rapidly as immediate lowering of blood pressure (BP) is necessary to minimize or reverse any...

  • UPPER EXTREMITY COMPARTMENT SYNDROME SECONDARY TO ACQUIRED FACTOR VIII INHIBITOR. Ilyas, Asif M.; Wisbeck, Jacob M.; Shaffer, Gene W.; Thoder, Joseph J. // Journal of Bone & Joint Surgery, American Volume;Jul2005, Vol. 87-A Issue 7, p1606 

    The article presents a case of a traumatic compartment syndrome of the right forearm in an elderly woman who required fasciotomy. A sixty-seven-year-old black woman with a medical history of hypertension and chronic obstructive pulmonary disease but no history of a bleeding disorder presented...

  • Nattokinase for Hypertension. Gaby, Alan R. // Townsend Letter;Jun2009, Issue 311, p39 

    The article presents a commentary about a study on nattokinase as a treatment for mild hypertension. Nattokinase is compared with placebo. The mechanism of action of nattokinase as an antihypertensive agent is emphasized. The significance of nattokinase treatment on plasma renin activity is...

  • Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. Gueyffier, F; Subtil, F; Bejan-Angoulvant, T; Zerbib, Y; Baguet, J P; Boivin, J M; Mercier, A; Leftheriotis, G; Gagnol, J P; Fauvel, J P; Giraud, C; Bricca, G; Maucort-Boulch, D; Erpeldinger, S // Journal of Human Hypertension;Jan2015, Vol. 29 Issue 1, p22 

    Current antihypertensive strategies do not take into account that individual characteristics may influence the magnitude of blood pressure (BP) reduction. Guidelines promote trial-and-error approaches with many different drugs. We conducted the Identification of the Determinants of the Efficacy...

  • When your patient's blood pressure won't come down. Wexler, Randy; Taylor, Christopher; Pleister, Adam; Feldman, David // Journal of Family Practice;Dec2009, Vol. 58 Issue 12, p640 

    The article presents two cases of individuals diagnosed with hypertension which are resistant and pseudo-resistant to the three-drug regimen of antihypertensive agents. The first case focuses on the management of pseudo-resistant hypertension which emphasizes the importance of compliance to...

  • Review: Lower-dose combination antihypertensive therapy is preferable to standard-dose single-drug therapy: COMMENTARY. Linden, Wolfgang // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p4 

    This article focuses on a study related to value of low dose combination treatment with blood pressure-lowering drugs, published in the 2003 issue of "British Medical Journal." The valuable and well-researched study investigates the effectiveness of the 5 most frequently used drugs for...

  • Safety and Tolerability of an Olmesartan Medoxomil-Based Regimen in Patients with Stage 1 Hypertension. Chrysant, Steven G. // Clinical Drug Investigation;2010, Vol. 30 Issue 7, p473 

    Background: One of the reasons for suboptimal blood pressure (BP) control in patients with hypertension is poor adherence to treatment, which may be caused by treatment-emergent adverse events. Therefore, it is crucial for an antihypertensive agent to provide a high level of efficacy without...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics